Innovative drugs for the treatment of primary headaches: migraine
https://doi.org/10.24411/2588-0519-2019-10077
Abstract
The article presents information about innovative drugs for the treatment of primary headaches (in particular, migraine), which are at the stages of clinical or preclinical studies, or were recently introduced to the foreign pharmaceutical market. The classes of these drugs, their mechanism of action, as well as the results of past studies are presents in article.
About the Authors
O. V. Reshetko
Saratov State Medical University named after VI. Razumovskiy of the Health Ministry of the Russian Federation
Russian Federation
Russian Federation
Reshetko Olga - MD, professor, Head of Department of Pharmacology
SPIN-code: 7569-7915
A. I. Grishin
Saratov State Medical University named after VI. Razumovskiy of the Health Ministry of the Russian Federation
Russian Federation
Grishin Anton - Post-graduate student, Department of Pharmacology
Russian Federation
Grishin Anton - Post-graduate student, Department of Pharmacology
References
1. who. int [internet]. Vsemirnaya Organizaciya Zdravoohraneniya. Informacionnyj byulleten Vsemirnoj Organizacii Zdravoohraneniya “Golovnye boli”, 2016 [dostup ot 7.05.2019]. Dostup po ssylke https://www.who.int/ru/news-room/fact-sheets/detail/headache-disorders (In Russ).
2. Sidorenko I. Novye podkhody k lecheniyu golovnoi boli napryazheniya. NeiroNews. 2013;4(2):66-68. (In Russ).
3. International Headache Society 2018. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. 2018;38(1):1-211. DOI: 10.1177/0333102417738202
4. Osipova VV. Pervichnye golovnye boli: klinika, diagnostika, terapiya. Informatsionnoe pis’mo (dlya nevrologov, terapevtov, vrachei obshchei praktiki). Rostov-na-Donu.: Izdatel’stvo Antei. 2011. (In Russ).
5. Osipova VV. Pervichnye golovnye boli: diagnostika i lechenie. Metodicheskie rekomendatsii. (In Russ). URL: https://clck.ru/Jcagx
6. Koe-chto eshche o migreni. Nauka i zhizn. 2001;12. (In Russ).
7. Sadokha KA, Golovko TG. Rol’ serotonina v patogeneze i lechenii migreni. Meditsinskie novosti. 2005;(4):40-43. (In Russ).
8. Agosti RM. 5-HT1F- and 5-HT7-receptor agonists for the treatment of migraines. NS & Neurological Disorders — Drug Targets. 2007;6(4):235-237.
9. Phebus LA, Ramadan NM, Skljarevski V, et al. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia. 2003;23(8):776-785.
10. Azimova YuE, Rachin AP, Ishchenko KA, et al. Innovatsionnye metody lecheniya migreni. Rossiiskii meditsinskii zhurnal. 2015;23(30):27-30. (In Russ).
11. Dubenko OYe. Calcitonin gene-related peptide in migraine:the pathogenetic factor and therapeutic target (review). Mezhdunarodnyi nevrologicheskii zhurnal. 2018;(2):38-44. (In Russ). DOI: 10.22141/2224-0713.2.96.2018.130481
12. Gomez-Mancilla B, Cutler NR, Leibowitz MT. Safety and Efficacy of PNU-142633, a Selective 5-HT1D Agonist, in Patients with Acute Migraine. Cefalgia. 2001;21(7):727-732. DOI: 10.1111/j.1468-2982.2001.00208.x
13. Brenchat A, et al. Role of peripheral versus spinal 5-HT(7) receptors in the modulation of pain undersensitizing conditions. European Journal of pain. 2012;16(1):72-81. DOI: 10.1016/j.ejpain.2011.07.004
14. Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001;358(9289): 1230-1234. DOI: 10.1016/s0140-6736(01)06347-4
15. clinicaltrials.gov [Internet]. A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT00384774
16. clinicaltrials.gov [Internet]. Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT00883051
17. Ferrari MD, Frkkil M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan — a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170-1178. DOI: 10.1177/0333102410375512
18. Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, doseranging study. Lancet Neurology. 2012;11(5):405-413. DOI: 10.1016/S1474-4422(12)70047-9
19. clinicaltrials.gov [Internet]. Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine (SPARTAN) [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT02605174
20. clinicaltrials.gov [Internet]. An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine (GLADIATOR) [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT02565186
21. FierceBiotech [Internet]. Eli Lilly files for FDA approval of migraine drug lasmiditan [cited 2019 May 7]. Available from https://www.fiercebiotech.com/biotech/lilly-files-for-fda-approval-migraine-drug-lasmiditan
22. Health Central [Internet]. New GCRP Migraine Treatments in Development — March, 2016, Report [cited 2019 May 7]. Available from https://www.healthcentral.com/article/new-gcrp-migraine-treatments-in-development-march-2016-report
23. Gang Yao, Tingmin Yu, Ximei Han, et al. Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis. Neural Regen Res. 2013;8(10):938-947. DOI: 10.3969/j.issn.1673-5374.2013.10.009
24. Ho TW, Mannix LK, Assaid C, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70(16):1304-1312. DOI: 10.1212/01.WNL.0000286940.29755.61
25. clinicaltrials.gov [Internet]. MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT00797667
26. clinicaltrials.gov [Internet]. Trial in Adult Subjects With Acute Migraines [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03461757
27. MPR [Internet]. Rimegepant Zydis ODT Beneficial in Phase 3 Migraine Trial [cited 2019 May 7]. Available from https://www.empr.com/home/news/drugs-in-the-pipeline/rimegepant-zydis-odt-beneficial-in-phase-3-migraine-trial/
28. clinicaltrials.gov [Internet]. Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03732638
29. Drugs.com [Internet]. Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant [cited 2019 May 7]. Available from https://www.drugs.com/clinical_trials/biohaven-announces-completion-pre-nda-meeting-fda-oral-cgrp-receptor-antagonist-rimegepant-18098.html
30. Allergan [Internet]. Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine [cited 2019 May 7]. Available from https://www.allergan.com/news/news/thomson-reuters/allergan-announces-fda-acceptance-of-new-drug-appl
31. clinicaltrials.gov [Internet]. Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine (ACHIEVE II) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02867709
32. clinicaltrials.gov [Internet]. Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine (ACHIEVE I) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02828020
33. clinicaltrials.gov [Internet]. An Extension Study to Evaluate the LongTerm Safety and Tolerability of Ubrogepant in the Treatment of Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02873221
34. Xu C, Shi L, Rao S, et al. EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP. The Journal of Headache and Pain. 2014 Sep;54(Suppl. 1):1417-1418. DOI: 10.1186/1129-2377-15-S1-G43
35. Pharma World Magazine [Internet]. Erenumab to prevent migraine: results from phase III STRIBE [cited 2019 May 7]. Available from http://www.pharmaworldmagazine.com/erenumab-prevent-migraine-results-phase-iii-stribe/
36. Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting [Internet]. [cited 2019 May 7] Available from: https://www.novartis.com/news/media-releases/novartis-presents-data-demonstrating-efficacy-amg-334-erenumab-migraine
37. fda.gov [Internet]. FDA approves novel preventive treatment for migraine [cited 2019 May 7]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-preventive-treatment-migraine
38. TheGuardian.com [Internet]. First drug to prevent chronic migraines approved by EU [cited 2019 May 7]. Available from: https://www.theguardian.com/science/2018/jul/31/first-ever-pill-to-prevent-chronic-migraines-approved-by-eu
39. Novartis [Internet]. Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine [cite 2019 May 7]. Available from https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-aimovigr-erenumab-prevention-migraine
40. Drugs.com [Internet]. Aimovig Approval History [cited 2019 May 7]. Available from https://www.drugs.com/history/aimovig.html
41. biospace.com [Internet]. Pfizer Inc. To Acquire Rinat Neuroscience Corporation [cited 2019 May 7]. Available from https://www.biospace.com/ article/releases/pfizer-inc-to-acquire-rinat-neuroscience-corporation-/
42. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. Journal of the American Medical Association. 2018 May;319(19):1999-2008. DOI: 10.1001/jama.2018.4853
43. Silberstein SD, McAllister P, Ning X, et al. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinicaltrials.gov. Headache: The journal of Head and Face Pain. 2019;59(6):880-890. DOI:10.1111/head.13534
44. Medscape [Internet]. FDA Approves Fremanezumab (Ajovy) for Migraine Prevention [cited 2019 May 7]. Available from https://www.medscape.com/viewarticle/902071
45. PMLive.com [Internet]. Teva’s migraine injection approved in Europe [cited 2019 May 7]. Available from https://www.pmlive.com/pharma_news/tevas_migraine_injection_approved_in_europe_1283616
46. businesswire.com [Internet] Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults [cited 2019 May 7]. Available from https://www.businesswire.com/news/home/20190401005452/en/
47. Drugs.com [Internet]. Fremanezumab [cited 2019 May 7]. Available from https://www.drugs.com/mtm/fremanezumab.html
48. clinicaltrials.gov [Internet]. Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study (EVOLVE-1) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02614183
49. clinicaltrials.gov [Internet]. Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study (EVOLVE-2) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02614196
50. clinicaltrials.gov [Internet] Evaluation of Galcanezumab in the Prevention of Chronic Migraine (REGAIN). [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02614261
51. CNBC [Internet]. US FDA approves Lilly migraine drug at a price that is the same as its rivals [cited 019 May 7]. Available from https://www.cnbc.com/2018/09/28/us-fda-approves-lilly-migraine-drug-at-a-price-that-is-the-same-as-its-rivals.html
52. Фармацевтический вестник [интернет]. Еврокомиссия одобрила Emgality для профилактики мигрени [доступ от 7.05.2019]. Доступно по ссылке https://pharmvestnik.ru/content/news/Evrokomissiya-odobrila-Emgality-dlya-profilaktiki-migreni.html
53. Drugs.com [Internet]. Galcanezumab [cited 2019 May 7]. Available from https://www.drugs.com/mtm/galcanezumab.html
54. grls.rosminzdrav.ru [интернет]. Государственный реестр лекарственных средств. Оценка эффективности и безопасности галканезумаба у пациентов с эпизодической мигренью [доступ от 7.05.2019]. Доступ по ссылке http://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=f2bb0510-0db1-4661-ba61-f26f0a1e42f0&CIPermGUID=B76D68CF-AB7B-4FD9-95E8-7A9B4F453F7B
55. Alder BioPharmaceuticals, Inc [Internet]. Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention [cited 2019 May 7]. Available from https://investor.alderbio.com/news-releases/news-release-details/alder-announces-eptinezumab-significantly-reduces-migraine-risk
56. Rossijskaya Farmacevtika [internet]. FDA odobrilo preparat dlya lecheniya epizodicheskoj klasternoj golovnoj boli [dostup ot 5.06.2019]. Dostup po ssylke http://pharmapractice.ru/156333 (In Russ).
57. GK Remedium [internet]. Alder uspeshno ispytala novyj preparat dlya lecheniya migreni [dostup ot 7.05.2019] . Dostup po ssylke http://remedium.ru/news/detail.php?ID=73186 (In Russ).
58. Alder BioPharmaceuticals, Inc [Internet]. Eptinezumab [cited 2019 may 2017]. Available from https://investor.alderbio.com/news-releases/ news-release-details/alder-announces-eptinezumab-significantly-reduces-migraine-riskhttps://www.alderbio.com/pipeline/eptinezumab/
59. Rubio-Beltran E, Correnti E, Deen M, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018;19(1). DOI:10.1186/s10194-018-0893-8
60. Moldovan Loomis C, Dutzar B, Ojala E, et al. Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide. Journal of Pharmacology and Experimental Therapeutics. 2019;369(1):26-36. DOI:10.1124/jpet.118.253443
61. Alder BioPharmaceuticals, Inc [Internet]. Alder BioPharmaceuticals Reports First Quarter 2019 Financial and Operating Results [cited 2019 May 7]. Available from https://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticalsr-reports-first-quarter-2019-financial
62. clinicaltrials.gov [Internet]. Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention [cited 2019 May 7]. [Available from https://clinicaltrials.gov/ct2/show/NCT03238781
63. Gratton S, Cossack M. Answering the Call: A Prospective Look at the Role of Timolol Eye Drops in the Treatment of Acute Migraine. Missouri Medicine. 2018;115(6):520-521.
64. clinicaltrials.gov [Internet]. A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03836664
65. Ionis [Internet]. Ionis Innovation: Our antisense-powered pipeline [cited 2019 May 7] // Available from https://www.ionispharma.com/ionis-innovation/pipeline/
66. clinicaltrials.gov [Internet]. Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03108469
67. Tepper S, Dodick D, Schmidt P, Kellerman D. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches. Headache: The Journal of Head and Face Pain. 2019;59(4):509-517. DOI:10.1111/head.13482
68. clinicaltrials.gov [Internet]. A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine (ADAM) [cited 2019 May 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT03282227
69. ZosanoPharma [Internet]. Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study [cited 2019 May 7]. Available from http://ir.zosanopharma.com/news-releases/news-release-details/zosano-treats-over-4000-migraines-and-reaches-important-goal
Review
For citations:
Reshetko O.V., Grishin A.I. Innovative drugs for the treatment of primary headaches: migraine. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2019;(2):95-104. (In Russ.) https://doi.org/10.24411/2588-0519-2019-10077
Views:
1061
Email this article 